PT-141 (Bremelanotide) is a cyclic heptapeptide analogue of Melanotan II, acting as a non-selective melanocortin receptor agonist. In research settings, it is investigated for its interactions with central melanocortin pathways independent of the vascular system, making it a subject of interest in studies on autonomic and neuroendocrine response models.